Clinical trial NCT02848742: Dermal Cryotherapy for Treatment of Pigmented Lesions
Official title: Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pigmented Skin Lesion
Lead sponsor: R2 Dermatology
Sponsor class: INDUSTRY
First posted: 2016-07-28
Enrollment: 377
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign pigmented lesions.

Detailed description: This study is a prospective, non-randomized, multi-center study of the Dermal Cooling System to verify that the device causes a reduction in pigmentation in benign pigmented lesions, and to determine at what parameters the device is most effective.

Eligibility criteria: Inclusion Criteria:

1. Male or female subjects \> 18 years of age.
2. Subject has one or more benign pigmented lesions (e.g., solar lentigines, melasma, freckles, café au lait, nevi, or hyperpigmentation), in an area suitable for treatment
3. Subject is willing to have up to 40 treatment sites and/or an area up to 8 square inches treated depending on the size and nature of the lesions identified.
4. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
5. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated areas for the duration of the study, including the follow-up period, if requested.
6. Subject has read and signed a written informed consent form.

Exclusion Criteria:

1. Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery)
2. Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period
3. Scars or tattoos in the location of the treatment sites
4. History of vitiligo, eczema, or psoriasis in the area of treatment
5. History of melanoma
6. Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.
7. History of abnormal wound healing or abnormal scarring
8. Inability or unwillingness to comply with the study requirements.
9. Current enrollment in a clinical study of any other unapproved investigational drug or device.
10. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

Primary outcomes:
measure: Reduction of pigmentation in treated lesions
timeFrame: 90 days
Secondary outcomes:
measure: Evaluation of device- or procedure-related adverse events
timeFrame: 0 to 12 months
Other outcomes:
Locations:
city: Walnut Creek
country: United States
facility: Diablo Clinical Research
state: California
city: Vancouver
country: Canada
facility: Arbutus Laser Centre
state: British Columbia
Study officials:
affiliation: R2 Dermatology, Inc.
name: Kristine Tatsutani, PhD
role: STUDY_DIRECTOR
References: